Original article

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids

in Japanese hemophiliacs

Yuji Kashiwakura[1,*], Nemekhbayar Baatartsogt[1,*], Shoji Yamazaki[2], Azusa Nagao[3], Kagehiro

Amano[4], Nobuaki Suzuki[5], Tadashi Matsushita[5], Akihiro Sawada[6], Satoshi Higasa[6], Naoya

Yamazaki[7], Teruhisa Fujii[7], Taemi Ogura[8], Hideyuki Takedani[9], Masashi Taki[10], Takeshi

Matsumoto[11], Jun Yamanouchi[12], Michio Sakai[13], Masako Nishikawa[14], Yutaka Yatomi[14], Koji

Yada[15], Keiji Nogami[15], Ryota Watano[16], Takafumi Hiramoto[1], Morisada Hayakawa[1,17],

Nobuhiko Kamoshita[1,17], Akihiro Kume[2,17], Hiroaki Mizukami[16,17], Shizukiyo Ishikawa[18],

Yoichi Sakata[1], and Tsukasa Ohmori[1,17]

[1]Department of Biochemistry, Jichi Medical University School of Medicine, 3311-1 Yakushiji,

Shimotsuke, Tochigi, Japan

[2]Clinical Research Center, Jichi Medical University Hospital, 3311-1 Yakushiji, Shimotsuke,

Tochigi, Japan

[3]Department of Blood Coagulation, Ogikubo Hospital, 3-1-24 Imagawa, Suginami, Tokyo

167-0035, Japan

[4]Department of Laboratory Medicine, Tokyo Medical University Hospital, 6-7-1,

Nishishinjuku, Shinjuku, Tokyo 160-0023, Japan

[5]Department of Transfusion Medicine, Nagoya University Hospital, 65 Tsurumai, Showa,

Nagoya, Aichi 466-8560, Japan

[6]Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, 1-1

Mukogawa, Nishinomiya, Hyogo 633-8501, Japan

[7]Hemophilia Treatment Center, Hiroshima University Hospital, 1-2-3 Kasumi, Minami,

Hiroshima, Hiroshima 734-8551, Japan

[8]Hemophilia Treatment Center, Shizuoka Children's Hospital, 860 Urushiyama, Aoi,

Shizuoka, Shizuoka 420-8660, Japan

[9]Department of Joint Surgery, IMSUT Hospital, The University of Tokyo, 4-6-1 Shirokanedai,

Minato, Tokyo 108-8639, Japan

[10]Department of Pediatrics, St. Marianna University School of Medicine Hospital, 2-16-1

Sugao, Miyamae, Kawasaki, Kanagawa 216-8511, Japan

[11]Department of Transfusion Medicine and Cell Therapy, Mie University, 2-174 Edobashi,

Tsu, Mie 514-8507, Japan

[12]Division of Blood Transfusion and Cell Therapy, Ehime University Hospital, 454

Shitsukawa, Toon, Ehime 791-0204, Japan

[13]Department of Pediatrics, Munakata Suikokai General Hospital, 5-7-1 Himaki, Fukutsu,

Fukuoka 811-3298, Japan

[14]Department of Clinical Laboratory, The University of Tokyo Hospital, 7-3-1 Hongo,

Bunkyo, Tokyo 113-8655, Japan

[15]Department of Pediatrics, Nara Medical University Hospital, 840 Shijo, Kashihara, Nara

634-8522, Japan

[16]Division of Gene Therapy, Center for Molecular Medicine, Jichi Medical University, 3311-1

Yakushiji, Shimotsuke, Tochigi 329-0498, Japan

[17]Center for Gene Therapy Research, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke,

Tochigi 329-0498, Japan

[18]Center for Information, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi

329-0498, Japan

[*]These authors contributed equally.

Correspondence should be addressed to T.O. (tohmori@jichi.ac.jp). Department of

Biochemistry, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke,

Tochigi 329-0498, Japan; Tel: +81-285-58-7324; FAX: +81-285-44-2185

Short title: Prevalence of AAV neutralizing antibody in Japan

Abstract

Adeno-associated virus (AAV) vectors are promising modalities of gene therapy to address

unmet medical needs. However, anti-AAV neutralizing antibodies (NAbs) hamper the

vector-mediated therapeutic effect. Therefore, the NAb prevalence in the target population is

vital in designing clinical trials with AAV vectors. Hence, updating the seroprevalence of

anti-AAV NAbs, herein we analyzed sera from 100 healthy individuals and 216 hemophiliacs

in Japan. In both groups, the overall seroprevalence against various AAV serotypes was

20%–30%, and the ratio of NAb-positive population increased with age. The seroprevalence

did not differ between healthy participants and hemophiliacs and was not biased by the

concomitant blood-borne viral infections. The high neutralizing activity, which strongly

inhibits the transduction with all serotypes *in vitro*, was mostly found in the 60s or older age.

The multivariate analysis suggested that "60s or older age" was the only independent factor

related to the high titer of NAbs. Conversely, a large proportion of younger hemophiliacs was

seronegative, rendering them eligible for AAV-mediated gene therapy in Japan. Compared

with our previous study, the peak of seroprevalences has shifted to older populations,

indicating natural AAV exposure in the elderly has occurred in their youth but not during the

last decade.

INTRODUCTION

Adeno-associated virus (AAV) vectors have been recently applied to *in vivo* gene therapy for various inherited diseases, including hemophilia. The expression of exogenous genes by systemic administration of an AAV vector is hindered by the presence of anti-AAV neutralizing antibodies (NAbs) related to previous AAV infection[1]. To date, most clinical trials for AAV-mediated hemophilia gene therapy have targeted only patients without NAbs against the AAV serotype used. Thus, it is essential to elucidate the seroprevalence of NAb before clinical trials.

Surveys for the seroprevalence of anti-AAV NAbs have shown broadly varying results, ranging from 2.2% to 96.6%[2–8]. Several factors appear to account for the prevalence of NAbs, including the geographical location. For example, high seroprevalence (~96.6%) has been reported in India[4], China[3], and Korea[5], compared with Europe[6], the United States[7], and Japan[8]. A recent global study of hemophilia A suggested the highest seropositivity to AAV5 in South Africa, Russia, Italy, and France compared with the United Kingdom, the United States, Germany, and Brazil[9]. Other factors, including ethnicity and age, are also known to affect the seroprevalence[3,7,9,10]. Previously, we reported that the seroprevalence in 40 years or older was much higher than those in younger populations in Japan[8]. Besides, seroprevalences differed among AAV serotypes. The seroprevalence against Clade B and C (AAV2 and AAV3B) that

naturally infects humans displayed higher seropositivity than other serotypes, including Clade

D and F (AAV8 and AAV9) [2,7,11–13].

This study aimed to determine the seroprevalence of NAbs against various AAV

serotypes and NAb titers in hemophiliacs and healthy individuals in Japan, in order to

estimate the number of patients with hemophilia eligible for future gene therapy in this

cross-sectional study. We also explored the underling factors that influence seroprevalence

and NAb titers. Our results will make it possible to discuss the mechanism of seroconversion

and changes in NAb titers over time by comparing the results of this study with those of our

previous survey conducted 10 years ago.

RESULTS

Study participants

We obtained 100 serum samples from each of 10 healthy men and women in the 20s, 30s, 40s,

50s, and 60s age range, and 227 hemophiliacs in Japan. Only the Japanese (not included other

ethnicities) were enrolled in this study. Based on the exclusion criteria, 11 patients using

emicizumab were excluded, resulting the total number of analyzed hemophiliacs as 216. Table

1 shows the profile of hemophiliacs and healthy volunteers in this study.

The seroprevalence of NAb against several AAV serotypes

We first assessed the seroprevalence of NAbs against various AAV serotypes in the healthy

participants and hemophiliacs. The seroprevalence of NAbs to AAV1, AAV2, AAV3B, AAV5,

AAV6, AAV7, AAV8, AAV9, and AAVrh10 was 20%–27% in healthy participants and

20.4%–29.2% in hemophiliacs (Figure 1A and B). No significant differences were observed

in the frequency among serotypes (Figure 1A and B). In addition, the frequencies between

patients and healthy participants were not significantly different, either (data not shown).

When the cutoff NAb titer was increased from 1:1 to 1:10, 1:20, 1:50, and 1:100, the

seroprevalence gradually decreased to 14%–20%, 11%–18%, 6%–17%, and 3%–16% in

healthy participants, and 14.4%–21.3%, 11.6%–19.4%, 7.9%–17.1%, and 5.6%–14.4% in

hemophiliacs, respectively (Figure 1E and 1F).

Then, we examined the NAb titers against each serotype (Figure 1C and D). The

NAb titers against AAV3B were higher than those with AAV5, AAV8, and AAV9 in healthy

participants, and higher than those against all serotypes, except AAV1 and AAV6, in

hemophiliacs (Figure 1C and D). We observed no significant difference between healthy

participants and patients in NAb titer of every AAV serotype (data not shown).

The influence of sex, age, type and severities of hemophilia, and viral infections on the

seroprevalence of NAb

Next, seroprevalence in males and females in healthy participants was compared. No

difference was noted in seropositivity and NAb titers between men and women (data not

shown). We further examined the impact of age on the seroprevalence and NAb titer (Figure

2). The seroprevalence of NAb was relatively low in the 20s, 30s, 40s, and 50s, and we

observed no clear difference in the prevalence of each serotype when classified by age in

these populations. Although the prevalence of AAV6 was 0% in 20s of healthy participants,

there was no statistical difference of the prevalence between AAV6 and other serotypes (data

not shown). In contrast, the seroprevalence was significantly higher in the 60s or older age

than younger subjects (Figure 2, Figure S1 and S2; Table S1). No difference was observed in

the prevalence between healthy participants and hemophiliacs by age group (data not shown).

Furthermore, a comparison of the NAb titers between healthy participants and hemophiliacs

revealed a small but significant difference between AAV8 NAbs in the 60s (Table S2).

144   In addition, we compared the seroprevalence and NAb titer between the type of

hemophilia and the severity. No age difference was observed between hemophilia A and B

(Figure S3A). The mean NAb prevalence was higher in hemophilia B patients than in

hemophilia A, although the difference was not statistically significant (Figure S3B). However,

the NAb titers were markedly higher in hemophilia B (Figure S3C). The severity of

hemophilia did not influence the seroprevalence and NAb titer (data not shown).

Then, we determined whether the previous infection of hepatitis C virus (HCV),

hepatitis B virus (HBV), and human immunodeficiency virus (HIV) affected anti-AAV NAbs

(data not shown). The age of patients with a history of HCV and HIV, but not HBV, was

markedly older than those without infections (data not shown). In addition, the concomitant

infection of HCV, HBV, and HIV did not affect the relevance of NAbs. Besides, the NAb

titers of several AAVs were significantly higher in HCV-positive participants. However, we

observed no significant differences for those aged <50 years (data not shown). We further

compared the prevalence between eastern and western region in Japan, and did not find any

difference between two geographical regions (data not shown).

Cross-reaction of NAbs with different serotypes

We examined the cross-reactivity of NAbs against multiple AAV serotypes. As shown in

Figure 3, one-half of the NAbs reacted with all the AAV serotypes examined, which, in turn,

were mostly found in participants aged 50 years or older, irrespective of the presence of

hemophilia (Figure 3A and B). In contrast, NAbs reacting with only a single AAV serotype

were found mostly in the 20–40 age groups (Figure 3A and B). The number of subjects

without NAbs against any AAV serotypes in healthy volunteers and hemophilia patients was

63 (63%, 63/100) and 149 (69%, 149/216), respectively. Antibody titers were strikingly high

when NAbs reacted with all serotypes (Figure 3C and D). Next, a multivariate logistic

regression analysis was performed to identify participants with NAb cross-reacted with all

serotypes. We included the variables of age (10–50s age group vs. 60 or older group), type of

hemophilia (A vs. B), severity (mild and moderate vs. severe), HCV (negative vs. positive),

HBV (negative vs. positive), and HIV (negative vs. positive). The age (60 years or older) was

the only independent variable to determine the participants with NAbs reacted with multiple

AAV serotypes (Table 2).

Correlation of NAb titers among serotypes

We next examined the correlation of NAb titers among serotypes. The NAb titers of all the

serotypes exhibited strong cross-correlations with each other ($P < 0.00001$ by Spearman's

rank correlation coefficient; Figure 4). Figure 4A shows the topology based on the similarity

of the capsid sequences of various serotypes. The correlation of NAb titers was high between

AAV1 and AAV6 (Figure 4B and C). Conversely, the correlation between NAbs to AAV5, the

most distant serotype as per the topology, and those to the other serotypes was relatively low

(Figure 4B and C). The factor analysis to identify latent variables and determine the

variability of NAb titers among serotypes suggested that only one factor explained 89.9% of

the variation (Figure 4D).

Comparison with other ethnicity

Finally, we compared the abovementioned results with the NAb seroprevalence in other

populations. To identify ethnical differences, sera from 10 Caucasians and 10

African–Americans aged 19–29 years in the United States were purchased. We selected

subjects with hemophilia aged 19–29 years and healthy subjects aged 20s (same age group as

US subjects) for comparison with healthy US subjects. The prevalence in Caucasians was

0%–20%, not much different from those in young Japanese (Figure 5). However, most

African–Americans possessed NAb against AAVs (Figure 5). The prevalence of

African–Americans, but not Caucasians, was significantly higher than those of age-matched

Japanese hemophilia patient group and healthy subjects ($P<0.0001$ in AAV1, AAV2, AAV3B,

AAV6, AAV7, AAV8, and AAV9; $P=0.0004$ in AAV5; $P=0.0008$ in AAVrh10 by chi-square

test).

DISCUSSION

Gene therapy by intravenous AAV vector administration has been clinically applied to

patients with hemophilia and neurological disorders[14]. In Japan, onasemnogene abeparvovec

was approved as the first AAV gene therapy drug in 2020, for children aged <2 years with

spinal muscular atrophy[15]. As the NAbs against AAV inhibit the efficacy of gene therapy with

intravenous injection of AAV vectors, it is imperative to know the prevalence of NAbs in the

region where the gene therapy is to be introduced before the clinical trial. This study

measured the latest prevalence of NAbs and NAb titers against various AAV serotypes in

Japan and demonstrated that the current seroprevalence of NAbs in Japan was one of the

lowest among other countries. According to the recent survey in Japan[16], there are 6,909 total

hemophilia patients (5,657 with hemophilia A and 1,252 with hemophilia B) in Japan. Based

on our survey of NAb prevalence, we estimated that 4,892–5,500 hemophilia (4,005–4,503

hemophilia A, and 886–997 hemophilia B) would be eligible for gene therapy using AAV

vectors. Thus, many hemophiliacs, and possibly other target diseases of gene therapy, in Japan,

especially in younger age groups, would benefit from AAV-mediated gene therapy.

In this study, the only demographical determining factor of the NAb prevalence was

age, and the cutoff age in the Japanese was 60 years. Factor analysis also suggested that age

was the only factor to determine NAb titer. Although several studies have consistently

reported the increase in seropositivity according to age[9,10,17], no survey has presented a clear

distinction from certain age group(s). Moreover, when one obtains AAV NAb though natural

infection remains unclear. A study of 4-year-follow-up reported that the seroconversion

occurred during early childhood for all serotypes[13]. Over the 6 months observation, very few

participants seroconverted and no geographic trend was noted[9]. In addition, the NAb titers

remained unchanged during the 6-year-follow-up in Duchenne muscular dystrophy[18].

Compared with our survey of Japanese participants conducted 10 years ago[8], the positive rate

of anti-AAV antibodies among 41–50 years has clearly declined from 80% to 20%, and the

peak of prevalence has clearly shifted to 60 years and older. These findings indicated that

endemic AAV infection leading to a demographical seroconversion has not occurred in the

past decade. Remarkably, the prevalence of AAV NAbs is similar to that of the hepatitis A

virus (HAV)[19]. A study examining 2430 sera from 12 Japanese prefectures in 2003 (17 years

ago from this study) reported a significant seropositivity of anti-HAV antibody in 45 years or

older[19]. As a result of the recent disappearance of endemic infection, the age-specific

seroprevalence of anti-HAV antibody had directly shifted to the right (older ages) over the

past 30 years[19]. HAV causes acute hepatitis in humans and its primary transmission occurs via

ingestion of food or water contaminated with HAV. The enhancement of sanitary conditions

has decreased the incidence of hepatitis A[19]. While respiratory infection is thought to be the

primary route of infection for AAV[20], adenoviruses can be transmitted through a variety of

routes, including droplet, contact, and fecal-oral transmission[21]. It is conceivable that the

prevalence of NAbs may increase in the environments where the opportunity for helper virus

infection is high. Perhaps, past (especially 50 years ago or more) sanitary environmental

factors in Japan might influence AAV infections in the elderly during their past childhood.

The NAb titer of the elderly participants tended to be high and reacted to multiple

AAV serotypes, whereas the NAb titer of younger participants tended to exhibit a low titer

that reacted with one or a few AAV serotype(s). Of note, NAbs for AAV show cross-reactivity

against multiple AAV serotypes[17,22]. Indeed, a longitudinal observational study of

chimpanzees over 10 years indicated that a single natural infection with AAV induced a

broadly cross-reactive NAb response to multiple AAV serotypes[23]. Natural AAV has a unique

biphasic lifecycle, including a productive and latent phase, and natural AAV2 (not AAV

vector) was inserted into the host genome at *AAVS1* locus in the latent phase[24]. Reportedly,

the latent AAV infection elicited NAbs but no cell-mediated immune responses in a

nonhuman primate model[25]. The subsequent infection of helper viruses such as herpesvirus

and adenovirus reactivates latent AAV, leading to proliferation and release of a large amount

of AAV[25]. Once AAV is integrated into the host chromosome, repeated helper virus infection

may facilitate the AAV proliferation and result in the high titer of NAbs against AAV. This is a

similar situation to the observation that multiple doses of the SARS-CoV-2 vaccine increase

NAb levels in strains with different antigenic properties[26]. Thus, repeated exposure to the

helper virus in a latent infection in youth could be accountable for the high titer of NAbs

reacted with multiple AAV serotypes in elderly participants.

This study suggests that the NAbs titers were consistently higher in patients with

hemophilia B than in patients with hemophilia A. We did not clarify the actual reason for

higher NAb titers in patients with hemophilia B, although a previous study suggested that

using a plasma-derived factor concentrate correlated with the seroprevalence of AAV8 NAb[27].

We could not obtain the detailed history of previous treatments with plasma-derived products

in individual cases, but the introduction of recombinant factor concentrates for hemophilia B

was considerably delayed in Japan. Recombinant factor VIII product was approved in 1993,

while recombinant factor IX was not available until 2010. Per the Nationwide Survey on

Coagulation Disorders 2015[28], 40.1% of patients with hemophilia B used plasma-derived

coagulation factors (252/629 patients, including bypass reagents), while 15.5% of those with

hemophilia A (439/2840 patients) in 2015. Perhaps, the delay in the widespread use of

recombinant preparations could correlate with the high titer of AAV in hemophilia B. AAV is

a small single-strand DNA virus belonging to the parvovirus family. Parvovirus cannot be

efficiently eliminated through viral inactivation of plasma-derived factor concentrates;

therefore, the use of plasma-derived factor preparations has been reported to increase the

seroprevalence of parvovirus B19 antibodies[29].

The intravenous injection of the AAV vector induces NAbs against the administered

serotype, making the intravenous readministration of the same serotype difficult[30,31].

Strategies for the second administration of the AAV vector should be considered for patients

who do not respond to the initial AAV gene therapy or for those who have a diminished

therapeutic response. To date, various preclinical studies have been conducted on the

treatment of patients with NAbs, *i.e.*, the administration of immunoglobulin G

(IgG)-degrading enzyme, simultaneous administration of empty capsid, plasma exchange,

intraportal administration, and use of rapamycin[18,32–35]. The most practical approach is to alter

the AAV serotype. Indeed, the readinistration of AAV1 vector reportedly succeeded in

monkeys and mice previously treated with AAV5[31]. Recently, the long-term observation of

hemophilia A dogs treated with AAV vector suggested NAbs elicited by the vector

administration was little cross-reactivity against other serotypes[36]. On the other hand, a report

of human clinical trials treated with AAV2 indicated the long-term persistence of NAbs

reacted with AAV5 and AAV8[37]. However, we cannot rule out the possibility that the patients

already possessed NAbs against other serotypes before the trial, because the seropositivity

against other serotypes was not assessed at baseline. Clinical trials to explore whether NAbs

for other AAV serotypes are produced after vector administration are also mandated for the

readministration.

This study has several limitations. First, we discussed the prevalence of NAbs and

time course compared with our previous reports, but we did not assess the same participants

over time. The most facilities in previous study[8] were included in the present study; the

previous study incorporated 6 facilities and 5 of them participated in this study (total 14

facilities in this study). We suspected that many previous participants were overlapped, but

unable to track which patients have been enrolled in the earlier study. Second, the variation of

methodology in the previous studies of NAb prevalence must be considered. In some studies,

total antibody binding with AAV capsid was measured, while others employed cell-based

neutralizing assay. We used a cell-based assay because total antibody assays detect the

binding antibody without any inhibitory effects[2,7,12]. On the other hand, the cell-based assay

depends on the cells used in the experiments and the multiplicity of infection (MOI) of AAV[38].

Assessment of neutralizing factors are known to be less sensitive than detecting binding

antibodies[4,7,12]. Accordingly, comparison among different studies should be interpreted with

caution. Indeed, the global study to measure the binding antibody against AAV5 showed that

the higher prevalence in Japanese (29.8%)[9], compared with those in our study. Furthermore,

the interpretation of the prevalence especially in African American population might be

overestimated, because the sera had little background information and the number of

specimens is limited. Hence, our comparative data with US population should be interpretated

with caution. Finally, the NAb titer to clinically suppress the AAV vector transduction

depends on the serotype and dose of the AAV vector to be administered[39]. Hence, it is

imperative to consider the threshold to judge "NAb-positive" for each drug to be

administered.

In conclusion, this study indicates that many patients would benefit from the

AAV-mediated gene therapy in Japan. In addition, the seroprevalence is significantly higher in

60 years or older age, and the population has high NAb titers cross-susceptibility to multiple

AAVs. Nevertheless, further data on the natural route of AAV infection in the environment,

changes in NAb titers after the administration of AAV vectors, and cross-reactivity to other

serotypes are warranted.

MATERIALS AND METHODS

Study protocol and participants

The Institutional Review Board at Jichi Medical University approved the study protocols

(permission number: A19-108), and we obtained written informed consent from all the

participants. The study was registered in UMIN-CTR (UMIN-CTR: UMIN000039069). We

enrolled 100 healthy volunteers (10 each from males and females in their 20s, 30s, 40s, 50s,

and 60s) and consecutive hemophiliacs from Jan 2020 to Mar 2021. The eligibility criteria for

hemophiliacs were hemophilia, Japanese-origin man, and age ≥10 years. The exclusion

criteria were as follows: 1) Participants unable to give written consent; 2) Participants being

treated with antibody drugs including emicizumab; 3) Participants being treated with systemic

(oral or injectable) immunosuppression; 4) Participants with possible immune abnormalities

such as inflammatory diseases; 5) Participants deemed ineligible by the principal investigator.

To minimize the possibility of nonspecific antibody reactions to the AAV vector, patients

treated with antibody drugs, including emicizumab, were excluded.

　　　　The cross-sectional study was conducted to investigate the seroprevalence of

anti-AAV NAbs in hemophiliacs in Japan. The number of samples required for the analysis

was first estimated to be 94.65, with a margin of 10% error to analyze the parent target

population (6455 hemophiliacs in Japan, the National Survey of Hemostatic Disorders[40]).

Therefore, we originally aimed to enroll each of 100 hemophiliacs and healthy volunteers for

the study. After enrollment, the target number of hemophilia cases was changed to 200

because the number of patients collaborating in the study was higher than expected during the

enrollment period. This change improved the error margin to 7%, further increasing the

accuracy of the study results. Healthy volunteers were recruited only from one facility (Jichi

Medical University), while hemophiliacs were recruited from 14 facilities in Japan. Each

facility enrolled 4–36 hemophilia patients.

Variables

For healthy participants, information was obtained on age and sex. For hemophiliacs,

information on age, type and severity of hemophilia, history of viral infection, and

coagulation factor preparation used was obtained. After obtaining informed consent, 10 mL of

whole blood was collected by venipuncture with vacuum blood collection tubes

(VENOJECT®II, TEROMO Corp., Tokyo, Japan) and a 22G needle. The tubes were allowed

to stand for 30 min at room temperature, and serum was obtained by centrifugation at 2,000 g

for 10 min. Then, the serum was aliquoted in 1 mL and stored at −80°C until analysis. The

primary endpoint of this study is to determine the percentage of seroprevalence, and to

enumerate the gross number of hemophiliacs who will benefit from AAV-mediated gene

therapy in Japan. The secondary endpoints were: (1) the correlation of age, sex, viral infection,

and types of hemophilia with the seroprevalence of NAb against AAV; and (ii) the

establishment of anti-AAV NAb assay.

Normal human sera (aged 19–29 years) from US Caucasians (5 male and female) and

US African–Americans (5 male and female) were purchased from Precision for Medicine

(Norton, MA).

AAV vector construction

We introduced a DNA cassette comprising the luciferase gene or the secreted type of the

NanoLuc gene driven by the CAG promoter and SV40 polyA between internal terminal

repeats of pAAV-CMV (Takara Bio, Shiga, Japan). pRC1, 2, 5, and 6 (for the production of

AAV1, 2, 5, and 6, respectively) were purchased from Takara Bio. The capsid sequences of

AAV8, AAV9, and AAV3B were synthesized in GenScript Japan (Tokyo Japan) and then

cloned into the pRC plasmid. The plasmids for the production of AAV7 (#112863) and

AAVrh10 (#112866) were obtained from Addgene (Watertown, MA). Next, the AAV vector

was produced by the transfection of AAVpro293 cells (Takara Bio) with three plasmid

transfections (pAAV, pRC, and pHelper; Helper-free system). The AAV vector was isolated by

CsCl-based ultracentrifugation, as described previously[41]. We confirmed that our AAV vector

contained >80% of full particles by analytical ultracentrifugation (data not shown). Finally,

the titer of the AAV vector was determined, as described previously[42].

Measurement of anti-AAV NAb

The sera from the subjects were heat-inactivated (56°C, 30 min) and diluted with fetal bovine

serum (FBS; Thermo Fisher Scientific, Waltham, MA) to 1:1–1:3,000, and then incubated

with an AAV vector 1:1 for 1 h at 37°C. Then, the mixture was added to a 96-well plate

seeded with Huh-7 cells in triplicate at MOI 1500. We essentially used luciferase as a reporter

gene to measure AAV transduction. As the transduction efficacy of Huh-7 with AAV7, AAV9,

and AAVrh10 expressing luciferase was lower than the target relative light unit (RLU =

10,000) in the preliminary experiment (data not shown), we used the secreted type of

NanoLuc (secNanoLuc) for transduction with AAV7, AAV9, and rh10. Moreover, MOI 150

was used in the case with AAV6 because high transduction efficacy might inhibit the

detection of NAb. After 48-h incubation, cells were lysed with 50 μL of 1× Passive Lysis

Buffer (Promega, Madison, WI) for the luciferase assay and then stored in a deep freezer. To

measure the secNanoLuc activity, 80 μL of the supernatant was collected and mixed with 20

μL of 5× Passive Lysis Buffer (Promega) and stored in a deep freezer. After thawing frozen

samples at room temperature, 10 μL of lysates or supernatants were added to a 96-well plate

(Berthold Technologies, Bad Wildbad, Germany). The 96-well plate was placed on a

luminometer (Centro LB 960, Berthold Technologies), and 50 µL of the Luciferase Assay

Reagent (Promega) or Nano-Glo® Luciferase Assay Reagent (Promega) was injected into

each well using an automatic injector. The delay and measurement times were set for 2 and 10

s, respectively. All measurements were done at room temperature and completed within 15

min. First, all samples were screened at the dilution of 1:1, and positive samples were selected

for further experiments to determine the NAb titer. The serum that inhibited >50% vector

transduction was considered a positive sample. The sera of positive samples were diluted with

FBS to 1:3, 1:10, 1:30, 1:100, 1:300, 1:1000, and 1:3000, and then the inhibition of vector

transduction was assessed. Next, we estimated antibody titers that neutralized 50% vector

transduction (ND_{50}) by nonlinear regression (inhibitor vs. normalized response, variable

slope) using GraphPad Prism 9 (GraphPad, San Diego, CA). We considered 1:1 as ND_{50} of

positive samples not to neutralize the vector transduction at 1:3 dilution. On the contrary,

ND_{50} to neutralize >50% vector transduction at 1:3000 dilution considered as 1:3000. We

employed 1:1 as the cutoff value for NAb-positive in this study because our previous data

showed that a low dose of AAV8 vector (5×10^{11} vg/kg) was inhibited in mice whose serum

NAb titer was 1:1[42]. We consistently used human immunoglobulin (GAMMAGARD®, Shire

plc, Dublin, Ireland) as a positive control and confirmed that the variation of ND_{50} in each

measurement was within 3-fold. We compared this method with the method from our

previous study[8] and confirmed that ND_{50} of human immunoglobulin against AAV5 and AAV8

assessed by either of the methods was not statistically different ($P = 0.1347$ and $P = 0.3432$,

respectively).

Statistical analysis

All statistical analyses were performed with GraphPad Prism 9 or JMPpro 16 (SAS Institute,

Cary, NC). The categorical variables are presented as percentages. The continuous variables,

e.g., age and NAb titers, are presented with each data point in figures. The normality of the

distribution of continuous variables was examined using the Kolmogorov–Smirnov test. As

the titers of NAb were not normally distributed (data not shown), we performed

non-parametric testing for the comparison. Between-group differences in frequencies were

examined with the Fisher's extract test, while differences in frequencies among ≥3 groups

were examined with the χ^2 test for trend. In addition, values between the two groups were

compared with the Mann–Whitney U test. The differences between two groups containing >3

groups were determined by the Friedman test (when each row was matched) or the

Kruskal–Wallis test (when each row was not matched) with the posthoc multiple comparison

test. Posthoc pairwise comparison between the groups (*i.e.*, patients vs. healthy volunteers)

among >3 groups (*i.e.*, age groups) was analyzed using the two-way analysis of variance with

a posthoc multiple comparison test. The correlation coefficient was measured using

Spearman's rank correlation coefficient. We applied factor analysis to identify latent factors to

explain the variance. Furthermore, the logistic regression analysis was used to examine the

correlation of independent variables with one dichotomous dependent variable. We did not

obtain data on HCV, HIV, and HBV in three, three, and six cases, respectively. The patients

with missing data were excluded from the comparison between those with and without viral

infection. In contrast, we included all participants in the multivariate analysis. In this study, *P*

< 0.05 was considered statistically significant. Besides, we created the topological

phylogenetic tree using the maximum likelihood method with Molecular Evolutionary

Genetics Analysis 11 software (https://www.megasoftware.net/home).

ACKNOWLEDGMENTS

This work was supported by AMED [JP18pc0101030]. Optima XE-90 were subsidized by

JKA through its promotion funds from KEIRIN RACE. We thank Sachiyo Kamimura, Mika

Kishimoto, Yaeko Suto, Tamaki Aoki, Mai Hayashi, Yuiko Ogihara, Nagako Sekiya, Noguchi

Tomoko, Hiromi Ozaki, and Hiroko Hayakawa of Jichi Medical University for their technical

assistance. Moreover, we gratefully appreciate the healthy volunteers and the hemophiliacs

who participated in this study. The authors would like to thank Enago (www.enago.jp) for the

English language review.

AUTHOR CONTRIBUTIONS

Y.K. conducted the experiments, analyzed the data, and wrote and revised the manuscript.

N.B., R.W. and T.H. conducted the experiments, analyzed the data, and revised the manuscript.

S.Y. designed the study, conducted the experiments, and revised the manuscript. A.N., K.A., N.S., T.M., A.S., S.H. N.Y., T.F., T.O., H.T., M.T., T.M., J.Y., M.S., M.N., Y.Y., K.Y., and K.N. recruited the study participants and obtained serum and data from the participants. M.H., N.K., A.K., H.M., and Y.S. analyzed the data and revised the manuscript. S.I. supervised all statistical analysis and revised the manuscript. T.O. designed the study, recruited the study participants, collected blood samples from all healthy volunteers, analyzed the data, and wrote and revised the manuscript. All authors approved the final version of the manuscript.

DECLARATION OF INTERESTS

All authors have no competing financial interests to declare.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author, [T.O.], upon reasonable request.

Keywords: Antibodies, Neutralizing, Dependovirus, Treatment Outcome, Genetic Therapy, Virus Vector

REFERENCES

1.   Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J.E., Ozelo,

M.C., Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in

hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat.

Med. *12*, 342–347. 10.1038/nm1358.

2.   Andrzejewski, S., Murali, A., Ramlogan-Steel, C., Edwards, K.P., Efron, N., Steel,

J.C., and Layton, C.J. (2019). Adeno-associated virus neutralising antibodies in type 1

diabetes mellitus. Gene Ther. *26*, 250–263. 10.1038/s41434-019-0076-5.

3.   Liu, Q., Huang, W., Zhang, H., Wang, Y., Zhao, J., Song, A., Xie, H., Zhao, C., Gao,

D., and Wang, Y. (2014). Neutralizing antibodies against AAV2, AAV5 and AAV8 in

healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV

vectors. Gene Ther. *21*, 732–738. 10.1038/gt.2014.47.

4.   Daniel, H.D.-J., Kumar, S., Kannangai, R., Lakshmi, K.M., Agbandje-Mckenna, M.,

Coleman, K., Srivastava, A., Srivastava, A., and Abraham, A.M. (2021). Prevalence of

Adeno-Associated Virus 3 Capsid Binding and Neutralizing Antibodies in Healthy and

Hemophilia B Individuals from India. Hum. Gene Ther. *32*, 451–457. 10.1089/hum.2020.258.

5.   Lee, S., Kang, I.K., Kim, J.H., Jung, B.K., Park, K., Chang, H., Lee, J.Y., and Lee, H.

(2019). Relationship Between Neutralizing Antibodies Against Adeno-Associated Virus in

the Vitreous and Serum: Effects on Retinal Gene Therapy. Transl. Vis. Sci. Technol. *8*, 14.

10.1167/tvst.8.2.14.

6.   Kruzik, A., Fetahagic, D., Hartlieb, B., Dorn, S., Koppensteiner, H., Horling, F.M.,

Scheiflinger, F., Reipert, B.M., and de la Rosa, M. (2019). Prevalence of

Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors.

Mol. Ther. - Methods Clin. Dev. *14*, 126–133. 10.1016/j.omtm.2019.05.014.

7.   Khatri, A., Shelke, R., Guan, S., and Somanathan, S. (2022). Higher Seroprevalence

of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in

the United States. Hum. Gene Ther. *33*, 442–450. 10.1089/hum.2021.243.

8.   Mimuro, J., Mizukami, H., Shima, M., Matsushita, T., Taki, M., Muto, S., Higasa, S.,

Sakai, M., Ohmori, T., Madoiwa, S., et al. (2014). The prevalence of neutralizing antibodies

against adeno-associated virus capsids is reduced in young Japanese individuals: Prevalence

of Antibodies Against AAV. J. Med. Virol. *86*, 1990–1997. 10.1002/jmv.23818.

9.   Klamroth, R., Hayes, G., Andreeva, T., Gregg, K., Suzuki, T., Mitha, I.H., Hardesty,

B., Shima, M., Pollock, T., Slev, P., et al. (2022). Global Seroprevalence of Pre-existing

Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Hum.

Gene Ther. *33*, 432–441. 10.1089/hum.2021.287.

10.   Greenberg, B., Butler, J., Felker, G.M., Ponikowski, P., Voors, A.A., Pogoda, J.M.,

Provost, R., Guerrero, J., Hajjar, R.J., and Zsebo, K.M. (2016). Prevalence of AAV1

neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced

heart failure. Gene Ther. *23*, 313–319. 10.1038/gt.2015.109.

11.   Calcedo, R., Vandenberghe, L.H., Gao, G., Lin, J., and Wilson, J.M. (2009).

Worldwide Epidemiology of Neutralizing Antibodies to Adeno☐Associated Viruses. J. Infect.

Dis. *199*, 381–390. 10.1086/595830.

12.   Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M.F.,

and Masurier, C. (2010). Prevalence of serum IgG and neutralizing factors against

adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications

for gene therapy using AAV vectors. Hum. Gene Ther. *21*, 704–712. 10.1089/hum.2009.182.

13.   Li, C., Narkbunnam, N., Samulski, R.J., Asokan, A., Hu, G., Jacobson, L.J.,

Manco-Johnson, M.J., Monahan, P.E., and The Joint Outcome Study Investigators (2012).

Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric

patients with hemophilia. Gene Ther. *19*, 288–294. 10.1038/gt.2011.90.

14.   Dunbar, C.E., High, K.A., Joung, J.K., Kohn, D.B., Ozawa, K., and Sadelain, M.

(2018). Gene therapy comes of age. Science *359*, eaan4672. 10.1126/science.aan4672.

15.   Reiss, U.M., Zhang, L., and Ohmori, T. (2021). Hemophilia gene therapy—New

country initiatives. Haemophilia *27*, 132–141. 10.1111/hae.14080.

16.   Japan Foundation for AIDS Prevention, (2021). Project entrusted by Ministry of

Health, Labor and Welfare. Nationwide Surv. Coagul. Disord. 2021.

https://api-net.jfap.or.jp/image/data/blood/r03_research/r03_research.pdf.

17.   Aronson, S.J., Veron, P., Collaud, F., Hubert, A., Delahais, V., Honnet, G., de Knegt,

R.J., Junge, N., Baumann, U., Di Giorgio, A., et al. (2019). Prevalence and Relevance of

Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for

Crigler–Najjar Syndrome. Hum. Gene Ther. *30*, 1297–1305. 10.1089/hum.2019.143.

18.   Leborgne, C., Latournerie, V., Boutin, S., Desgue, D., Quéré, A., Pignot, E., Collaud,

F., Charles, S., Simon Sola, M., Masat, E., et al. (2019). Prevalence and long-term monitoring

of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy

patients. Cell. Immunol. *342*, 103780. 10.1016/j.cellimm.2018.03.004.

19.   Kiyohara, T., Sato, T., Totsuka, A., Miyamura, T., Ito, T., and Yoneyama, T. (2007).

Shifting Seroepidemiology of Hepatitis A in Japan, 1973-2003. Microbiol. Immunol. *51*,

185–191. 10.1111/j.1348-0421.2007.tb03900.x.

20.   Chen, C.-L., Jensen, R.L., Schnepp, B.C., Connell, M.J., Shell, R., Sferra, T.J.,

Bartlett, J.S., Clark, K.R., and Johnson, P.R. (2005). Molecular characterization of

adeno-associated viruses infecting children. J. Virol. *79*, 14781–14792.

10.1128/JVI.79.23.14781-14792.2005.

21.   Lion, T. (2019). Adenovirus persistence, reactivation, and clinical management.

FEBS Lett. *593*, 3571–3582. 10.1002/1873-3468.13576.

22.   Perocheau, D.P., Cunningham, S.C., Lee, J., Antinao Diaz, J., Waddington, S.N.,

Gilmour, K., Eaglestone, S., Lisowski, L., Thrasher, A.J., Alexander, I.E., et al. (2019).

Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.

Hum. Gene Ther. *30*, 79–87. 10.1089/hum.2018.098.

23.   Calcedo, R., and Wilson, J.M. (2016). AAV Natural Infection Induces Broad

Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees. Hum.

Gene Ther. Clin. Dev. *27*, 79–82. 10.1089/humc.2016.048.

24.   Hamilton, H., Gomos, J., Berns, K.I., and Falck-Pedersen, E. (2004).

Adeno-Associated Virus Site-Specific Integration and AAVS1 Disruption. J. Virol. *78*,

7874–7882. 10.1128/JVI.78.15.7874-7882.2004.

25.   Hernandez, Y.J., Wang, J., Kearns, W.G., Loiler, S., Poirier, A., and Flotte, T.R.

(1999). Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated

Immune Responses in a Nonhuman Primate Model. J. Virol. *73*, 8549–8558.

10.1128/JVI.73.10.8549-8558.1999.

26.   Edara, V.V., Hudson, W.H., Xie, X., Ahmed, R., and Suthar, M.S. (2021).

Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.

JAMA *325*, 1896. 10.1001/jama.2021.4388.

27.   Stanford, S., Pink, R., Creagh, D., Clark, A., Lowe, G., Curry, N., Pasi, J., Perry, D.,

Fong, S., Hayes, G., et al. (2019). Adenovirus-associated antibodies in UK cohort of

hemophilia patients: A seroprevalence study of the presence of adenovirus-associated virus

vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with

hemophilia A. Res. Pract. Thromb. Haemost. *3*, 261–267. 10.1002/rth2.12177.

28.   Japan Foundation for AIDS Prevention, (2015). Project entrusted by Ministry of

Health, Labor and Welfare. Nationwide Surv. Coagul. Disord. 2015.

https://api-net.jfap.or.jp/image/data/blood/h27_research/h27_research.pdf.

29.   Mauser-Bunschoten, E. p., Zaaijer, H.L., van Drimmelen, A. a. J., de Vries, S.,

Roosendaal, G., van den Berg, H.M., and Lelie, P.N. (1998). High Prevalence of Parvovirus

B19 lgG Antibodies among Dutch Hemophilia Patients. Vox Sang. *74*, 225–227.

10.1046/j.1423-0410.1998.7440225.x.

30.   Nathwani, A.C., Reiss, U.M., Tuddenham, E.G.D., Rosales, C., Chowdary, P.,

McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014). Long-Term

Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B. N. Engl. J. Med. *371*,

1994–2004. 10.1056/NEJMoa1407309.

31.   Majowicz, A., Salas, D., Zabaleta, N., Rodríguez-Garcia, E., González-Aseguinolaza,

G., Petry, H., and Ferreira, V. (2017). Successful Repeated Hepatic Gene Delivery in Mice

and Non-human Primates Achieved by Sequential Administration of AAV5 ch and AAV1.

Mol. Ther. *25*, 1831–1842. 10.1016/j.ymthe.2017.05.003.

32.   Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J.,

Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. Overcoming Preexisting

Humoral Immunity to AAV Using Capsid Decoys. 10.

33.   Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F.,

Moullier, P., Benveniste, O., and Masurier, C. (2011). A 10 Patient Case Report on the

Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV)

Types 1, 2, 6, and 8. Mol. Ther. *19*, 2084–2091. 10.1038/mt.2011.108.

34.   Mimuro, J., Mizukami, H., Hishikawa, S., Ikemoto, T., Ishiwata, A., Sakata, A.,

Ohmori, T., Madoiwa, S., Ono, F., Ozawa, K., et al. (2013). Minimizing the Inhibitory Effect

of Neutralizing Antibody for Efficient Gene Expression in the Liver With Adeno-associated

Virus 8 Vectors. Mol. Ther. *21*, 318–323. 10.1038/mt.2012.258.

35.   Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G.,

Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018). Antigen-selective

modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables

successful vector re-administration. Nat. Commun. *9*, 4098. 10.1038/s41467-018-06621-3.

36.   Batty, P., Mo, A., Hurlbut, D., Ishida, J., Yates, B., Brown, C., Harpell, L.M., Hough,

C., Pender, A., Rimmer, E.K., et al. (2022). Long-Term Follow-up of Liver-Directed,

Adeno-Associated Vector-Mediated Gene Therapy in the Canine Model of Hemophilia A.

Blood, blood.2021014735. 10.1182/blood.2021014735.

37.   George, L.A., Ragni, M.V., Rasko, J.E.J., Raffini, L.J., Samelson-Jones, B.J., Ozelo,

M., Hazbon, M., Runowski, A.R., Wellman, J.A., Wachtel, K., et al. (2020). Long-Term

Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer:

AAV2-hFIX16 for Severe Hemophilia B. Mol. Ther. J. Am. Soc. Gene Ther. *28*, 2073–2082.

10.1016/j.ymthe.2020.06.001.

38.   Halbert, C.L., Miller, A.D., Mcnamara, S., Emerson, J., Gibson, R.L., Ramsey, B.,

and Aitken, M.L. (2006). Prevalence of Neutralizing Antibodies Against Adeno-Associated

Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal Populations: Implications for

Gene Therapy Using AAV Vectors. Hum. Gene Ther. *17*, 440–447.

10.1089/hum.2006.17.440.

39.   Majowicz, A., Nijmeijer, B., Lampen, M.H., Spronck, L., de Haan, M., Petry, H.,

van Deventer, S.J., Meyer, C., Tangelder, M., and Ferreira, V. (2019). Therapeutic hFIX

Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs

with Pre-existing Anti-AAV5 NABs. Mol. Ther. - Methods Clin. Dev. *14*, 27–36.

10.1016/j.omtm.2019.05.009.

40.   Japan Foundation for AIDS Prevention, (2017). Project entrusted by Ministry of

Health, Labor and Welfare. Nationwide Surv. Coagul. Disord. 2017.

https://api-net.jfap.or.jp/image/data/blood/h29_research/h29_research.pdf.

41.   Grieger, J.C., Choi, V.W., and Samulski, R.J. (2006). Production and

characterization of adeno-associated viral vectors. Nat. Protoc. *1*, 1412–1428.

10.1038/nprot.2006.207.

42.   Baatartsogt, N., Kashiwakura, Y., Hayakawa, M., Kamoshita, N., Hiramoto, T.,

Mizukami, H., and Ohmori, T. (2021). A sensitive and reproducible cell-based assay via

secNanoLuc to detect neutralizing antibody against adeno-associated virus vector capsid. Mol.

Ther. - Methods Clin. Dev. *22*, 162–171. 10.1016/j.omtm.2021.06.004.

Table 1. Characteristics of participants in this study

Parameter	Hemophiliacs (*n* = 216)	Hemophilia A (*n* = 175)	Hemophilia B (*n* = 41)	Healthy volunteers (*n* = 100)
Age at enrollment, mean ± SD, years	42.1 ± 16.9	42.1 ± 16.2	42 ± 19.5	43.6 ± 13.7
Age at enrollment, *n* (%)				
10–29 years old (10–20s)	59 (27.3)	45 (25.7)	14 (34.1)	20 (20)
30–39 years old (30s)	38 (17.6)	34 (19.4)	4 (9.8)	20 (20)
40–49 years old (40s)	44 (20.4)	35 (20.0)	9 (22.0)	20 (20)
50–59 years old (50s)	41 (19.0)	35 (20.0)	6 (14.6)	20 (20)
≥60 years (60s–)	34 (15.7)	26 (14.9)	8 (19.5)	20 (20)
Sex, *n* (%)				
Male	216 (100)	175 (100)	41 (100)	50 (50)
Female	0 (0)	0 (0)	0 (0)	50 (50)
Hemophilia A, *n* (%)	175 (81.0)			
Hemophilia B, *n* (%)	41 (19.0)			
Severity, *n* (%)				

Mild	26 (12.0)	20 (11.4)	6 (14.6)
Moderate	36 (16.7)	29 (16.6)	7 (17.1)
Severe	154 (71.3)	126 (72.0)	28 (68.3)
History of exposure to hepatitis B, n (%)	10 (4.6)*	4 (2.3) ***	2 (4.9)[‡‡]
History of exposure to hepatitis C, n (%)	107 (49.5)**	33 (18.9) **	19 (46.3)
History of exposure to HIV, n (%)	36 (16.7)**	5 (2.9)[‡]	11 (26.8)[‡‡]

*The data could not be obtained from 6 patients.

**The data could not be obtained from 3 patients.

***The data could not be obtained from 5 patients.

[‡] The data could not be obtained from 2 patients.

[‡‡] The data could not be obtained from 1 patient.

SD, standard deviation

Table 2. Multivariate logistic regression analysis to examine neutralizing antibody against the multiple AAV serotypes

Variables	Reference [0]	β	Standard error	P (Prob > χ^2)	Odds ratio (95% CI)
Age	10–50s	−1.0868764	0.2438719	<0.0001*	8.79 (3.45–23.66)
Type	Hemophilia A	−0.2478077	0.2495874	0.3208	1.64 (0.60–4.29)
Severity	Mild and moderate	−0.1175052	0.2347134	0.6166	1.26 (0.52–3.32)
HBV	None	−0.0136041	0.4602926	0.9764	1.03 (0.13–5.33)
HCV	None	−0.2251832	0.2490041	0.3658	1.57 (0.59–4.22)
HIV	None	0.07752898	0.2903081	0.7894	0.85 (0.26–2.60)

640   AAV, adeno-associated virus; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus

 FIGURE LEGENDS

 Figure 1. Seroprevalence and neutralizing titer of NAbs against each AAV serotype. (A

 and B) The seroprevalence of NAbs against each AAV in healthy volunteers (A) and

 hemophiliacs (B). The statistical difference among serotypes was analyzed using the χ^2 test

 for trend. (C and D) The NAb titer against each AAV serotype in healthy volunteers (C) and

 hemophiliacs (D). (E and F) The seroprevalence of NAbs against each AAV in healthy

 volunteers (E) and hemophiliacs (F) at several thresholds. A positive rate is shown by each

 threshold of serum dilution factor (1:1, 1:10, 1:20, 1:50, and 1:100). Statistical differences

 among serotypes were analyzed using the Friedman test with the posthoc multiple

 comparisons test. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, and $****P < 0.0001$. AAV,

 adeno-associated virus; NAbs, neutralizing antibodies; n.s., not significant.

 Figure 2. Differences in the seroprevalence of AAV NAbs among age groups. The

 seroprevalence of NAbs against each AAV of each age group (10–20s, 30s, 40s, 50s, 60s, or

 older) in healthy volunteers (A) and hemophiliacs (B). AAV, adeno-associated virus; NAbs,

 neutralizing antibodies.

Figure 3. Cross-reaction of NAb with different AAV serotypes. (A and B) The number of

serotypes inhibited by each positive serum in healthy volunteers (A) and hemophiliacs (B).

The bars are shown to identify the proportion of age groups (10–20s, 30s, 40s, 50s, 60s, or

older). (C and D) The comparison of NAb titers between the cases with antibodies to all

serotypes (9 positives) and others (1–8 positives) in healthy volunteers (C) and hemophiliacs

(D). Between-group differences were determined by the Mann–Whitney U test. $*P < 0.05$,

$**P < 0.01$, $***P < 0.001$, and $****P < 0.0001$. AAV, adeno-associated virus; NAbs,

neutralizing antibodies; n.s., not significant.

Figure 4. Correlation between NAb titers against each AAV serotype. (A) The topology is

based on the similarity of the capsid sequences of various AAV serotypes. (B and C) The

correlation between NAb titers against each AAV serotype in healthy volunteers (B) and

hemophiliacs (C). The correlation coefficient was measured using the Spearman rank

correlation coefficient. (D) The factor analysis to identify latent variables determines the

variability of NAb titers among serotypes. AAV, adeno-associated virus; CR, contribution

ratio; CCR, cumulative contribution ratio; NAbs, neutralizing antibody.

Figure 5. Differences in the seroprevalence of AAV NAbs among ethnicities at young

ages. The seroprevalence of NAbs against each AAV in healthy volunteers (20s, $n = 20$) and

hemophiliacs (aged 19–29 years, selected from the hemophiliacs, $n =$37) in Japan, Caucasians

($n = $10), and African–Americans ($n = $10). AAV, adeno-associated virus; NAbs, neutralizing

antibodies.

Figure 1 Kashiwakura, *et al.*

A

Healthy volunteers

B

Hemophiliacs

Figure 2 Kashiwakura, *et al.*

Figure 3 Kashiwakura, *et al.*

Figure 4 Kashiwakura, et al.

Figure 5 Kashiwakura, *et al.*